References
1. Saxby N, Painter C, Kench A, King S, Crowder T, Van der Haak N.Nutrition guidelines for cystic fibrosis in Australia and New
Zealand. Sydney: Thoracic Society of Australia and New Zealand; 2017.
2. Nichols AL, Davies JC, Jones D, Carr SB. Restoration of exocrine
pancreatic function in older children with cystic fibrosis on ivacaftor.Paediatr Respir Rev. 2020;35:99-102.
3. Poli P, Conforti C, Gennari E, Padoan R. Transitory pancreatic
insufficiency in cystic fibrosis children. J Cyst Fibros.2020;19(1):e5-e6.
4. Davies JC, Cunningham S, Harris WT, et al. Safety, pharmacokinetics,
and pharmacodynamics of ivacaftor in patients aged 2–5 years with
cystic fibrosis and a CFTR gating mutation (KIWI): an open-label,
single-arm study. The Lancet Respiratory Medicine.2016;4(2):107-115.
5. Rosenfeld M, Wainwright CE, Higgins M, et al. Ivacaftor treatment of
cystic fibrosis in children aged 12 to <24 months and with a
CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. The
Lancet Respiratory Medicine. 2018;6(7):545-553.